Biogen took the same approach with Avonex: approval was based on biomarkers (T1 and T2 lesion reduction) but in the longitudinal trial published ~15 years later, it was shown that Avonex seems to have no clinical impact on MS. And it still sells $1b per year of it.
Market Data 
Markets 
AI
